Sort
25,944 grants matching “neurodegeneration”
A Phase 3 pivotal trial of AGB101 to slow progression in MCI due to Alzheimer's Disease
$4,000,000Richard C. Mohs · Agenebio, Inc. · R56 · FY2017 · AG
NDC for the Optical Control of Biological Function
$4,000,000Ehud Isacoff · University Of California Berkeley · PN2 · FY2013 · EY
ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE
$3,987,763Reisa A. Sperling · University Of California, San Diego · U19 · FY2015 · AG
The role of pericytes in the aging brain and pathogenesis and treatment of neurodegeneration, and Alzheimer's A-beta and tau pathology
$3,981,640Justin Kawika Ichida · University Of Southern California · RF1 · FY2019 · AG
The A3 Study: Ante-Amyloid Prevention of Alzheimer's disease
$3,981,411Reisa A. Sperling · Brigham And Women'S Hospital · R01 · FY2019 · AG
The A3 Study: Ante-Amyloid Prevention of Alzheimer's disease
$3,980,365Reisa A. Sperling · Brigham And Women'S Hospital · R01 · FY2021 · AG
The A3 Study: Ante-Amyloid Prevention of Alzheimer's disease
$3,979,320Reisa A. Sperling · Brigham And Women'S Hospital · R01 · FY2023 · AG
Reproductive risk factors for Alzheimer's disease dementia and pathology
$3,974,970Walter A Rocca · Mayo Clinic Rochester · RF1 · FY2017 · AG
Center without Walls for Imaging Proteinopathies with PET (CW2IP2)
$3,974,587Robert H Mach · University Of Pennsylvania · U19 · FY2023 · NS
Study to Uncover Pathways to Exceptional Cognitive Resilience in Aging (SUPERAging)
$3,972,149Emily J Rogalski · Northwestern University At Chicago · U19 · FY2022 · AG
Proteinopathies of the Aging Central Nervous System
$3,948,699Lennart Mucke · J. David Gladstone Institutes · P01 · FY2011 · AG
Systems-level functional proteomics analysis assemblies in Alzheimer's disease and mouse models of tauopathy
$3,945,190Benjamin L Wolozin · Boston University Medical Campus · RF1 · FY2019 · AG
Capturing the molecular complexity of Alzheimer's disease through the lens of RNA binding proteins
$3,944,412Benjamin L Wolozin · Boston University Medical Campus · RF1 · FY2018 · AG
Procurement and Characterization of Postmortem Brain Tissue
$3,942,053Stefano Marenco · National Institute Of Mental Health · ZIC · FY2025 · MH
Mechanisms, modeling and therapies of retinal and macular neurodegeneration
$3,937,795Anand Swaroop · National Eye Institute · ZIA · FY2024 · EY
PET Radiopharmaceutical Sciences
$3,936,544Victor W Pike · National Institute Of Mental Health · ZIA · FY2019 · MH
Development of novel therapies for FAD
$3,927,945Jie Shen · Brigham And Women'S Hospital · RF1 · FY2019 · AG
Structure of amyloid fibrils in human neurodegenerative diseases and aging
$3,924,261Ruben Vidal · Indiana University Indianapolis · RF1 · FY2023 · NS
Alzheimers Disease Patient Registry
$3,907,919Ronald C Petersen · Mayo Clinic Rochester · U01 · FY2023 · AG
Alzheimers Disease Patient Registry
$3,907,919Ronald C Petersen · Mayo Clinic Rochester · U01 · FY2022 · AG
Subclinical Vascular Contributions to Alzheimer's Disease: The Multi Ethnic Study of Atherosclerosis (MESA) Multisite Studyof AD
$3,899,242Timothy M. Hughes · Wake Forest University Health Sciences · R01 · FY2021 · AG
PET Radiopharmaceutical Sciences
$3,889,768Victor W Pike · National Institute Of Mental Health · Z01 · FY2008 · MH
Alzheimers Disease Patient Registry
$3,874,548Ronald C Petersen · Mayo Clinic Rochester · U01 · FY2020 · AG
Alzheimers Disease Patient Registry
$3,874,548Ronald C Petersen · Mayo Clinic Rochester · U01 · FY2021 · AG
Alzheimers Disease Patient Registry
$3,874,548Ronald C Petersen · Mayo Clinic Rochester · U01 · FY2019 · AG